Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Oncotarget

Volumn 7, Issue 28, 2016, Pages 44583-44595

  Ai, Bo ^a   Liu, Huiquan ^a   Huang, Yu ^a   Peng, Ping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Biomarker; Circulating cell free DNA; Meta analysis; Non small cell lung cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; CELL FREE NUCLEIC ACID; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; GENE MUTATION; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT CODING; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; BLOOD; DISEASE FREE SURVIVAL; GENETICS; LUNG TUMOR; META ANALYSIS; MUTATION; OUTCOME ASSESSMENT; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL-FREE NUCLEIC ACIDS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; GENOTYPE; HUMANS; LUNG NEOPLASMS; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84978658389     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10069     Document Type: Article

References (57)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 CA Cancer J Clin. 2015; 65:87-108.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
3. De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol. 2015. doi: 10.1016/j.molonc.2015.12.001. [Epub ahead of print].
4. Gray ES, Rizos H, Reid AL et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6:42008-42018.
5. Carpinetti P, Donnard E, Bettoni F et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015; 6:38360-38371.
6. Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015; 90:128-134.
7. Xia S, Kohli M, Du M et al. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015; 6:16411-16421.
8. Stroun M, Maurice P, Vasioukhin V et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000; 906:161-168.
9. Catarino R, Coelho A, Araujo A et al. Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One. 2012; 7:e38559.
10. Szpechcinski A, Chorostowska-Wynimko J, Struniawski R et al. Cell-free DNA levels in plasma of patients with nonsmall-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015; 113:476-483.
11. Szpechcinski A, Rudzinski P, Kupis W et al. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 2016. doi: 10.1016/j.canlet.2016.02.002. [Epub ahead of print].
12. Zhang R, Shao F, Wu X et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010; 69:225-31.
13. Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol. 2015; 36:7-19.
14. Zhao X, Han RB, Zhao J et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration. 2013; 85:119-125.
15. Ishii H, Azuma K, Sakai K et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget. 2015; 6:30850-30858.
16. Bai H, Mao L, Wang HS et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV nonsmall-cell lung cancer. J Clin Oncol. 2009; 27:2653-2659.
17. Qiu M, Wang J, Xu Y et al. Circulating tumor DNA is effective for the detection of EGFR mutation in nonsmall cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015; 24:206-212.
18. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014; 4:6269.
19. Tissot C, Toffart AC, Villar S et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015; 46:1773-1780.
20. Dowler Nygaard A, Spindler KL, Pallisgaard N et al. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep. 2014; 31:969-974.
21. Bortolin MT, Tedeschi R, Bidoli E et al. Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy. Biomarkers. 2015; 20:422-428.
22. Li BT, Drilon A, Johnson ML et al. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancersdagger. Ann Oncol. 2016; 27:154-159.
23. Nygaard AD, Garm Spindler KL, Pallisgaard N et al. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013; 79:312-317.
24. Kimura H, Suminoe M, Kasahara K et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007; 97:778-784.
25. Camps C, Sirera R, Bremnes R et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer. 2005; 50:339-346.
26. Douillard JY, Ostoros G, Cobo M et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9:1345-1353.
27. Wang S, Han X, Hu X et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014; 430:63-70.
28. Vinayanuwattikun C, Winayanuwattikun P, Chantranuwat P et al. The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol. 2013; 139:67-76.
29. Sirera R, Bremnes RM, Cabrera A et al. Circulating DNA is a useful prognostic factor in patients with advanced nonsmall cell lung cancer. J Thorac Oncol. 2011; 6:286-290.
30. Lee YJ, Yoon KA, Han JY et al. Circulating cellfree DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res. 2011; 17:5179-5187.
31. Ludovini V, Pistola L, Gregorc V et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol. 2008; 3:365-373.
32. Camps C, Sirera R, Bremnes RM et al. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res. 2006; 26:4905-4909.
33. Gautschi O, Bigosch C, Huegli B et al. Circulating deoxyribonucleic Acid as prognostic marker in non-smallcell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004; 22:4157-4164.
34. Gautschi O, Huegli B, Ziegler A et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007; 254:265-273.
35. He C, Liu M, Zhou C et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009; 125:2393-2399.
36. Kimura H, Kasahara K, Kawaishi M et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006; 12:3915-3921.
37. Kim ST, Sung JS, Jo UH et al. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol. 2013; 30:328.
38. Li X, Ren R, Ren S et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol. 2014; 7:341-8.
39. Camps C, Jantus-Lewintre E, Cabrera A et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011; 72:365-369.
40. Karachaliou N, Mayo-de las Casas C, Queralt C et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol. 2015; 1:149-157.
41. Wang Z, Chen R, Wang S et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One. 2014; 9:e110780.
42. Punnoose EA, Atwal S, Liu W et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012; 18:2391-2401.
43. Zhuo ML, Wu MN, Zhao J et al. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl). 2011; 124:3510-3514.
44. Goto K, Ichinose Y, Ohe Y et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012; 7:115-121.
45. Thress KS, Brant R, Carr TH et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90:509-515.
46. Nygaard AD, Holdgaard PC, Spindler KL et al. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer. 2014; 110:363-368.
47. Sun W, Yuan X, Tian Y et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 2015; 8:95.
48. Ulivi P, Mercatali L, Casoni GL et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One. 2013; 8:e57401.
49. Newman AM, Bratman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20:548-554.
50. Szpechcinski A, Chorostowska-Wynimko J, Kupis W et al. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther. 2012; 12:S3-9.
51. Overman MJ, Modak J, Kopetz S et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013; 31:17-22.
52. Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008; 60:S3-9.
53. Russo A, Franchina T, Ricciardi GR et al. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015; 6:26814-26825.
54. Pan W, Yang Y, Zhu H et al. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget. 2016. doi: 10.18632/oncotarget.7080. [Epub ahead of print].
55. Dogan S, Shen R, Ang DC et al. Molecular epidemiology of EGFR and KRAS mutations in 3, 026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18:6169-6177.
56. Boch C, Kollmeier J, Roth A et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013; 3:e002560.
57. Weber B, Meldgaard P, Hager H et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014; 14:294.